{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:47:00Z","timestamp":1775645220405,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["336839"],"award-info":[{"award-number":["336839"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.trecan.2017.07.006","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:45:57Z","timestamp":1503535557000},"page":"621-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Targeting Inflammation to Improve Tumor Drug Delivery"],"prefix":"10.1016","volume":"3","author":[{"given":"Vasiliki","family":"Gkretsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lefteris C.","family":"Zacharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Triantafyllos","family":"Stylianopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2017.07.006_bib0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2017.07.006_bib0010","article-title":"Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity","volume":"6","author":"Martin","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.trecan.2017.07.006_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2017.07.006_bib0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fonc.2015.00214","article-title":"Remodeling components of the tumor microenvironment to enhance cancer therapy","volume":"5","author":"Gkretsi","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-chembioeng-061010-114300","article-title":"Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies","volume":"2","author":"Chauhan","year":"2011","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.trecan.2017.07.006_bib0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0035","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0040","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment","volume":"95","author":"Hobbs","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2017.07.006_bib0045","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2017.07.006_bib0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrc2895","article-title":"The shunt problem: control of functional shunting in normal and tumour vasculature","volume":"10","author":"Pries","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2017.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/onc.2013.121","article-title":"Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment","volume":"33","author":"Casazza","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2017.07.006_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2013.07.005","article-title":"Deciphering and reversing tumor immune suppression","volume":"39","author":"Motz","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.trecan.2017.07.006_bib0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2017.07.006_bib0070","doi-asserted-by":"crossref","DOI":"10.1115\/1.4034991","article-title":"The solid mechanics of cancer and strategies for improved therapy","volume":"139","author":"Stylianopoulos","year":"2017","journal-title":"J. Biomech. Eng."},{"key":"10.1016\/j.trecan.2017.07.006_bib0075","doi-asserted-by":"crossref","first-page":"15101","DOI":"10.1073\/pnas.1213353109","article-title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","volume":"109","author":"Stylianopoulos","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2017.07.006_bib0080","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2017.07.006_bib0085","doi-asserted-by":"crossref","DOI":"10.1038\/srep46140","article-title":"Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner","volume":"7","author":"Papageorgis","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.trecan.2017.07.006_bib0090","doi-asserted-by":"crossref","first-page":"24506","DOI":"10.18632\/oncotarget.15534","article-title":"Pirfenidone normalizes the tumor microenvironment to improve chemotherapy","volume":"8","author":"Polydorou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2017.07.006_bib0095","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.07.006_bib0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2017.06.022","article-title":"Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy","volume":"261","author":"Mpekris","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.trecan.2017.07.006_bib0105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2017.07.006_bib0110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","article-title":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","volume":"25","author":"Rhim","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2017.07.006_bib0115","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0120","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.trecan.2017.07.006_bib0125","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.trecan.2017.07.006_bib0130","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1073\/pnas.1700340114","article-title":"Role of vascular normalization in benefit from metronomic chemotherapy","volume":"114","author":"Mpekris","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2017.07.006_bib0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andre","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0140","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2017.07.006_bib0145","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2017.07.006_bib0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2017.07.006_bib0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2796.2000.00742.x","article-title":"Infections as a major preventable cause of human cancer","volume":"248","author":"Kuper","year":"2000","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.trecan.2017.07.006_bib0160","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.suc.2015.08.001","article-title":"Colorectal neoplasia and inflammatory bowel disease","volume":"95","author":"Cannon","year":"2015","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.trecan.2017.07.006_bib0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-642-03503-6_6","article-title":"Inflammatory bowel disease and colon cancer","volume":"185","author":"Jawad","year":"2011","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.trecan.2017.07.006_bib0170","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3748\/wjg.v23.i3.472","article-title":"Incidental adenocarcinoma in patients undergoing surgery for stricturing Crohn\u2019s disease","volume":"23","author":"Kristo","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00535-016-1273-2","article-title":"Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis","volume":"52","author":"Takeda","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.micro.54.1.615","article-title":"The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer","volume":"54","author":"Ernst","year":"2000","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0185","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/micc.12270","article-title":"Obesity and cancer: an angiogenic and inflammatory link","volume":"23","author":"Fukumura","year":"2016","journal-title":"Microcirculation"},{"key":"10.1016\/j.trecan.2017.07.006_bib0190","doi-asserted-by":"crossref","DOI":"10.4161\/tisb.23805","article-title":"Locking endothelial junctions blocks leukocyte extravasation, but not in all tissues","volume":"1","author":"Kuppers","year":"2013","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.trecan.2017.07.006_bib0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/03009734.2015.1064501","article-title":"Vascular permeability \u2013 the essentials","volume":"120","author":"Claesson-Welsh","year":"2015","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.trecan.2017.07.006_bib0200","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1089\/ars.2005.7.1744","article-title":"The role of endothelial cells in the resolution of acute inflammation","volume":"7","author":"Kadl","year":"2005","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.trecan.2017.07.006_bib0205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/prd.12034","article-title":"Natural resolution of inflammation","volume":"63","author":"Freire","year":"2013","journal-title":"Periodontology 2000"},{"key":"10.1016\/j.trecan.2017.07.006_bib0210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd1383","article-title":"Inflammatory resolution: new opportunities for drug discovery","volume":"3","author":"Gilroy","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2017.07.006_bib0215","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tips.2007.02.003","article-title":"Inflammation and cancer: a failure of resolution?","volume":"28","author":"Lawrence","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.trecan.2017.07.006_bib0220","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri915","article-title":"Anti-inflammatory lipid mediators and insights into the resolution of inflammation","volume":"2","author":"Lawrence","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0225","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10555-011-9311-2","article-title":"Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer","volume":"30","author":"Janakiram","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.trecan.2017.07.006_bib0230","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.biocel.2013.09.018","article-title":"Resolvin D1 inhibits TGF-beta1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor\/formyl peptide receptor 2 and GPR32","volume":"45","author":"Lee","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0235","first-page":"71","article-title":"Resolution of cancer-promoting inflammation: a new approach for anticancer therapy","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0245","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev.med.51.1.511","article-title":"Nonsteroidal anti-inflammatory drugs and cancer prevention","volume":"51","author":"Baron","year":"2000","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.trecan.2017.07.006_bib0250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00001648-200101000-00015","article-title":"Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs","volume":"12","author":"Garcia-Rodriguez","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.trecan.2017.07.006_bib0255","doi-asserted-by":"crossref","first-page":"7908","DOI":"10.1038\/sj.onc.1203286","article-title":"The role of cyclooxygenases in inflammation, cancer, and development","volume":"18","author":"Williams","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2017.07.006_bib0260","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-3701-3-8","article-title":"Non-steroid anti-inflammatory drugs, prostaglandins, and cancer","volume":"3","author":"Allaj","year":"2013","journal-title":"Cell Biosci."},{"key":"10.1016\/j.trecan.2017.07.006_bib0265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.canlet.2013.09.001","article-title":"Impact of non-steroidal anti-inflammatory drugs on gastrointestinal cancers: current state-of-the science","volume":"345","author":"Sahin","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2017.07.006_bib0270","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3171\/jns.1986.65.2.0233","article-title":"Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model","volume":"65","author":"Reichman","year":"1986","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.trecan.2017.07.006_bib0275","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1167\/iovs.07-1527","article-title":"Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs","volume":"49","author":"Pakneshan","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.trecan.2017.07.006_bib0280","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JPR.S75160","article-title":"New insights into the use of currently available non-steroidal anti-inflammatory drugs","volume":"8","author":"Brune","year":"2015","journal-title":"J. Pain Res."},{"key":"10.1016\/j.trecan.2017.07.006_bib0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-065X.2008.00607.x","article-title":"The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance","volume":"222","author":"Allavena","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.trecan.2017.07.006_bib0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1615\/CritRevImmunol.v32.i6.10","article-title":"M1 and M2 macrophages: oracles of health and disease","volume":"32","author":"Mills","year":"2012","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0295","first-page":"10","article-title":"Cyclooxygenase-2 inhibition attenuates hypoxic cancer cells induced m2-polarization of macrophages","volume":"60","author":"Dubey","year":"2014","journal-title":"Cell. Mol. Biol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0300","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/carcin\/bgr128","article-title":"COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin\/+ mouse polyps","volume":"32","author":"Nakanishi","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trecan.2017.07.006_bib0305","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ijc.30424","article-title":"Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression","volume":"140","author":"Simoes","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2017.07.006_bib0310","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/sj.bjc.6605441","article-title":"Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial","volume":"101","author":"Bougnoux","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.trecan.2017.07.006_bib0315","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/310186","article-title":"Dietary omega-3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer","volume":"2013","author":"Merendino","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.trecan.2017.07.006_bib0320","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jnci\/djn324","article-title":"Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis","volume":"100","author":"Takkouche","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2017.07.006_bib0325","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000452315","article-title":"The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives","volume":"11","author":"Moris","year":"2016","journal-title":"Breast Care"},{"key":"10.1016\/j.trecan.2017.07.006_bib0330","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.drudis.2015.12.003","article-title":"COX-2 inhibitors: a novel strategy in the management of breast cancer","volume":"21","author":"Regulski","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.trecan.2017.07.006_bib0335","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trecan.2017.07.006_bib0340","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/01.COC.0000074147.22064.67","article-title":"Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth","volume":"26","author":"Liu","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0345","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MPA.0b013e3182a8d41f","article-title":"High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis","volume":"43","author":"Cui","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.trecan.2017.07.006_bib0350","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1365-2036.2007.03495.x","article-title":"Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories","volume":"26","author":"Capurso","year":"2007","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.trecan.2017.07.006_bib0355","first-page":"4356","article-title":"Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs","volume":"59","author":"Molina","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2017.07.006_bib0360","first-page":"2018","article-title":"Overexpression of cyclooxygenase-2 in carcinoma of the pancreas","volume":"5","author":"Okami","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2017.07.006_bib0365","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ctrv.2006.12.003","article-title":"Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma","volume":"33","author":"Zalatnai","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2017.07.006_bib0370","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1054\/drup.2001.0219","article-title":"Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives","volume":"4","author":"Dermond","year":"2001","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.trecan.2017.07.006_bib0375","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nm.2416","article-title":"Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2","volume":"17","author":"Lyons","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2017.07.006_bib0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/08982100801893978","article-title":"Utility of targeted glucocorticoids in cancer therapy","volume":"18","author":"Banciu","year":"2008","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.trecan.2017.07.006_bib0385","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2353\/ajpath.2010.100322","article-title":"Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?","volume":"177","author":"Serhan","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.trecan.2017.07.006_bib0390","series-title":"Goodman and Gilman\u2019s Manual of Pharmacology and Therapeutics","first-page":"430","article-title":"Analgesic-antipyretic and anti-inflammatory agents; pharmacotherapy of gout","author":"Burke","year":"2008"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317301541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803317301541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T10:51:41Z","timestamp":1535453501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803317301541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S2405803317301541"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2017.07.006","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Inflammation to Improve Tumor Drug Delivery","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2017.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}